Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011552
Filing Date
2025-08-14
Accepted
2025-08-14 16:04:24
Documents
64
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fencf-20250630x10q.htm   iXBRL 10-Q 1528363
2 EX-31.1 fencf-20250630xex31d1.htm EX-31.1 13851
3 EX-31.2 fencf-20250630xex31d2.htm EX-31.2 18433
4 EX-32.1 fencf-20250630xex32d1.htm EX-32.1 9263
5 EX-99.1 fencf-20250630xex99d1.htm EX-99.1 312180
6 GRAPHIC fencf-20250630xex99d1001.jpg GRAPHIC 3171
7 GRAPHIC fencf-20250630xex99d1002.jpg GRAPHIC 699
8 GRAPHIC fencf-20250630xex99d1003.jpg GRAPHIC 3079
  Complete submission text file 0001558370-25-011552.txt   7015322

Data Files

Seq Description Document Type Size
9 EX-101.SCH fencf-20250630.xsd EX-101.SCH 50195
10 EX-101.CAL fencf-20250630_cal.xml EX-101.CAL 40134
11 EX-101.DEF fencf-20250630_def.xml EX-101.DEF 199652
12 EX-101.LAB fencf-20250630_lab.xml EX-101.LAB 344069
13 EX-101.PRE fencf-20250630_pre.xml EX-101.PRE 312143
67 EXTRACTED XBRL INSTANCE DOCUMENT fencf-20250630x10q_htm.xml XML 1184506
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Filer) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-32295 | Film No.: 251218651
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)